TrialOncotarget2015

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.

Michal Podrazil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.